Zoetis Inc. (ZTS), the leading animal healthcare company, experienced a sharp decline of 8.16% in its stock price during the pre-market trading session on Thursday. The plummet was primarily driven by the company's underwhelming guidance for the year 2025, which fell short of Wall Street's expectations.
In its fourth-quarter earnings report, Zoetis forecasted its adjusted earnings per share (EPS) for 2025 to be in the range of $6.00 to $6.10, missing analysts' average estimate of $6.29. Additionally, the company projected its full-year revenue for 2025 to be between $9.23 billion and $9.38 billion, lower than the consensus estimate of $9.57 billion.
The disappointing outlook was attributed to several factors, including the impact of a stronger U.S. dollar and the divestiture of certain product portfolios, such as the medicated feed additive product line and certain water-soluble products, which were sold to Phibro Animal Health for $350 million. These divestitures had a slightly larger impact than initially anticipated, according to J.P. Morgan analyst Chris Schott.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。